Research ArticleCANCER IMMUNOLOGY

KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target

See allHide authors and affiliations

Science Immunology  09 Jul 2021:
Vol. 6, Issue 61, eabf9792
DOI: 10.1126/sciimmunol.abf9792

Article Information

vol. 6 no. 61

PubMed: 
Published By: 
History: 
  • Received December 2, 2020
  • Revision received April 22, 2021
  • Accepted May 28, 2021
  • .

Author Information

  1. Yao Wei1,,
  2. Xiaoxin Ren1,,
  3. Phillip M. Galbo Jr.1,2,
  4. Scott Moerdler1,3,
  5. Hao Wang1,
  6. R. Alejandro Sica1,4,
  7. Bijan Etemad-Gilbertson5,
  8. Lei Shi1,
  9. Liqiang Zhu1,
  10. Xudong Tang1,
  11. Qi Lin1,
  12. Mou Peng1,
  13. Fangxia Guan1,
  14. Deyou Zheng2,6,
  15. Jordan M. Chinai1 and
  16. Xingxing Zang1,4,7,*
  1. 1Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  2. 2Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  3. 3Department of Pediatrics, Children’s Hospital, Montefiore Medical Center, Bronx, NY 10461, USA.
  4. 4Department of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA.
  5. 5NextPoint Therapeutics Inc., Cambridge, MA 02142, USA.
  6. 6Departments of Neurology and Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  7. 7Department of Urology, Montefiore Medical Center, Bronx, NY 10461, USA.
  1. *Corresponding author. Email: xingxing.zang{at}einsteinmed.org
  • These authors contributed equally to this work.

Altmetric

Article usage

Article usage: July 2021 to July 2021

AbstractFullPdf
Jul 20219090618415

Stay Connected to Science Immunology